- Facing pharmacy trends for the remainder of the year
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- Senate passes Drug Quality and Security Act
- Americans more likely than others to prefer generics, study finds
INDIANAPOLIS — The U.S. District Court for the District of Delaware has upheld a patent held by Indianapolis-based drug maker Eli Lilly covering a chemotherapy drug, Lilly said Monday.
The case concerns a patent covering Alimta (pemetrexed) that expires in July 2016 and generic drug maker Teva Pharmaceutical Industries’ challenge to it.
According to Reuters, a district judge in New Jersey also ruled in favor of Bristol-Myers Squibb and Otsuka Pharmaceutical in a case involving their patent for the antipsychotic drug Abilify (aripiprazole). The patent expires in April 2015.